Budesonide mixed with surfactant did not affect neurodevelopmental outcomes at 6 or 18 months corrected age in observational cohorts
Autor: | Howard L. Williams, T Brett Kothe, Connie D. Anderson, F Sadiq, Justin B. Josephsen, Nikki Burleyson, Noah H. Hillman |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Budesonide
Pediatrics medicine.medical_specialty Affect (psychology) Bayley Scales of Infant Development Article 03 medical and health sciences Surface-Active Agents 0302 clinical medicine Pulmonary surfactant 030225 pediatrics medicine Humans Infant Very Low Birth Weight 030212 general & internal medicine Toddler Bronchopulmonary Dysplasia business.industry Infant Newborn Obstetrics and Gynecology Infant Pulmonary Surfactants Translational research medicine.disease Bronchopulmonary dysplasia Outcomes research Pediatrics Perinatology and Child Health Cohort Observational study business medicine.drug |
Zdroj: | Journal of Perinatology |
ISSN: | 1476-5543 0743-8346 |
Popis: | Background The addition of budesonide to surfactant in very-low-birth-weight infants with less severe RDS decreased bronchopulmonary dysplasia (BPD) severity. Long-term neurodevelopmental follow-up was needed to monitor for systemic effects of budesonide. Methods Infants ≤1250 g who received intratracheal budesonide (0.25 mg/kg) with surfactant (n = 173) were compared to a historical cohort who received surfactant alone (n = 294). Peabody Developmental Motor Scales II at 4-6 months corrected age and Bayley Scales of Infant & Toddler Development III at 18-22 months corrected age were compared. Results There were no differences in muscle tone or motor skills by Peabody exam. There were no differences in the cognitive, language, or motor domains between cohorts on Bayley III. Conclusions In a cohort of infants treated with budesonide mixed with surfactant, there were no differences in developmental outcomes at 4-6 months or 18-22 months corrected age. |
Databáze: | OpenAIRE |
Externí odkaz: |